Psoriasiform lesions (paradoxical adverse event) were observed in 10.1% of 583 anti-TNF-treated IBD patients in a 14-year retrospective sample, which was mostly found in patients with CD (CD: 10.8% and UC: 6.8%). This evidence concerns the gene TNF and inflammatory bowel disease.